Business Wire

DEEPTECH-LABS

Share
Europe’s Only Deeptech Demo Day: Deeptech Labs’ Unveil 6 New Accelerator Start-ups

Deeptech Labs , the accelerator and VC fund for post-Seed, pre-Series A deeptech companies will unveil its Spring cohort of 6 deeptech start-ups to an online audience of investors on 21st June. More than 120 VCs and Corporate Entities have previously attended its virtual demo days, demonstrating the significant and growing interest in the European deeptech sector.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220614005112/en/

Deeptech Labs is a Cambridge-based accelerator programme and VC fund, founded in 2020 by ARM, Cambridge Innovation Capital, Martlet Capital, Ewan Kirk and the University of Cambridge. The accelerator supports deeptech entrepreneurs as they move from prototype and proof of concept to scalable products and services, and connects them to Deeptech Labs’ extensive network of deeptech investors.

The Deeptech Labs accelerator programme and investment fund was founded to fill a significant gap in the European venture market and accelerate the growth of promising early-stage deeptech companies. Deeptech Labs supports its cohort companies through a specially-designed thirteen week accelerator programme, connecting founders with a global network of more than 50 world-leading deeptech entrepreneurs, technology experts and investors.

Watch Demo Day elevator pitches from the Spring ’22 cohort:

Anaphite (Bristol, UK) incorporates graphene into battery materials, to enable the creation of super-fast charge, long-range batteries - something that will have significant impact on the EV market.

  • Watch Anaphite’s 3-minute elevator pitch here

Toposens (Munich, Germany) is the world’s only 3D ultrasonic sensing technology for advanced collision avoidance. It uses echolocation and signal processing algorithms to make autonomous vehicles in the robotics and automotive industry smarter and safer.

  • Watch Toposens’ 3-minute elevator pitch here

SonicEdge (Shoham, Israel) has developed the world’s smallest speaker-in-chip that uses breakthrough ultrasound technology to completely transform the audio experience.

  • Watch SonicEdge’s 3-minute elevator pitch here

iKVA (Cambridge, UK) is an early-stage AI Knowledge Management company creating solutions for organisations to discover data and intelligently and proactively provide it to users when they need it, enabling better business insights.

  • Watch iKVA’s 3-minute elevator pitch here

Inovo Robotics (Guildford, UK) are democratising robotics with modular, no-code, low cost “cobots” that open up completely new opportunities for safe, flexible automation.

  • Watch Inovo Robotics’ 3-minute elevator pitch here

Nestwave (Paris, France) Nestwave provides advanced, IoT geolocation solutions to IoT modem and DSP vendors to significantly improve localization accuracy in critical indoor and dense urban environments while greatly reducing power consumption and solution footprint.

  • Watch Nestwave’s 3-minute elevator pitch here

Miles Kirby, CEO Deeptech Labs said, “Europe has a number of global advantages in deeptech – we have 50% of the world’s best universities and the highest number of highly cited research papers - but there’s a disparity when it comes to European investment in deeptech companies. European deeptech companies attract $33 billion compared to $144 billion in the US .

Thanks to our deeptech-specific accelerator programme, our cohort companies are stronger, more resilient and have highly focused go-to-market strategies and that’s why so many investors attend our Demo Days – and how we are helping to fix the European deeptech investment gap.”

  • Watch Miles’ 5 minute introduction to Deeptech Labs here .

Editors Notes

Deeptech Labs is an accelerator, VC fund, and the catalyst for deeptech success. Twice a year, its cohort of start-ups are embedded in a powerful network of successful entrepreneurs, expert practitioners, leading researchers, and deeptech organisations worldwide. Deeptech Labs is founded by ARM, Cambridge Innovation Capital, Martlet Capital, Ewan Kirk and the University of Cambridge - forefront institutions and individuals at the heart of the Cambridge and global technology ecosystems.

The company is headquartered in Cambridge, UK.

For more information, please visit dtl.vc

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 09:00:00 CET | Press release

SIAL Paris 2026 is more than ever the world’s must-attend food industry event With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global i

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release

Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye